Coeptis Therapeutics Inc (COEP)vsVertex Pharmaceuticals Inc (VRTX)
COEP
Coeptis Therapeutics Inc
$16.40
+1.17%
HEALTHCARE · Cap: $102.06M
VRTX
Vertex Pharmaceuticals Inc
$446.83
-0.03%
HEALTHCARE · Cap: $107.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 896305% more annual revenue ($12.22B vs $1.36M). VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
COEP
Avoid23
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+78.9%
Fair Value
$56.80
Current Price
$16.40
$40.40 discount
Margin of Safety
+53.1%
Fair Value
$952.53
Current Price
$446.83
$505.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 1564.0% year-over-year
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -136.9% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : COEP
The strongest argument for COEP centers on Revenue Growth. Revenue growth of 1564.0% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : COEP
The primary concerns for COEP are EPS Growth, Market Cap, Profit Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
COEP profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
VRTX carries more volatility with a beta of 0.30 — expect wider price swings.
COEP is growing revenue faster at 1564.0% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 23/100), backed by strong 35.5% margins. COEP offers better value entry with a 78.9% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Coeptis Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and markets brand-name and generic pharmaceuticals and cell therapy platforms for cancer patients. The company is headquartered in Wexford, Pennsylvania.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?